Age and preoperative total bilirubin level can stratify prognosis after extracorporeal pulsatile left ventricular assist device implantation

Circulation Journal

Volumn 75, Issue 1, 2011, Pages 122-128

  Shiga, Taro ^a   Kinugawa, Koichiro ^a   Hatano, Masaru ^a   Yao, Atsushi ^a   Nishimura, Takashi ^a   Endo, Miyoko ^a   Kato, Naoko ^a   Hirata, Yasunobu ^a   Kyo, Shunei ^a   Ono, Minoru ^a   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Heart failure; Heart assist device; Hemodynamics; Risk factor; Transplantation

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILIRUBIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; ARTIFICIAL HEART PACEMAKER; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; EXTRACORPOREAL CIRCULATION; FEMALE; HEART ASSIST DEVICE; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; JAPAN; LONG TERM CARE; MALE; MULTIPLE ORGAN FAILURE; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; WOUND INFECTION;

EID: 78651262544     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0770     Document Type: Article

References (24)

1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-e235.
2. Taylor DO, Stehlik J, Edwards LB, Aurora P, Christie JD, Dobbels F, et al. Registry of the international society for heart and lung transplantation: Twenty-sixth official adult heart transplant report-2009. J Heart Lung Transplant 2009; 28: 1007-1022.
3. Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD, et al. Use of a continuous-flow device in patients awaiting heart transplantation N Engl J Med 2007; 357: 885-896.
4. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361: 2241-2251.
5. Saito S, Matsumiya G, Sakaguchi T, Fujita T, Kuratani T, Ichikawa H, et al. Fifteen-year experience with toyobo paracorporeal left ventricular assist system. J Artif Organs 2009; 12: 27-34.
6. Nishimura T, Kyo S. High-dose carvedilol therapy for mechanical circulatory assisted patients. J Artif Organs 2010; 13: 88-91.
7. El-Banayosy A, Arusoglu L, Kizner L, Tenderich G, Boethig D, Minami K, et al. Predictors of survival in patients bridged to transplantation with the Thoratec VAD device: A single-center retrospective study on more than 100 patients. J Heart Lung Transplant 2000; 19: 964-968.
8. Frazier OH, Rose EA, Oz MC, Dembitsky W, McCarthy P, Radovancevic B, et al. Multi center clinical evaluation of the Heart-mate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg 2001; 122: 1186-1195.
9. Holman WL, Kormos RL, Naftel DC, Miller MA, Pagani FD, Blume E, et al. Predictors of death and transplant in patients with a mechanical circulatory support device: A multi-institutional study. J Heart Lung Transplant 2009; 28: 44-50.
10. Farrar DJ. Preoperative predictors of survival in patients with Tho-ratec ventricular assist devices as a bridge to heart transplantation [Thoratec ventricular assist device principal investigators]. J Heart Lung Transplant 1994; 13: 93-100; discussion 100-101.
11. Matthews JC, Koelling TM, Pagani FD, Aaronson KD. The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol 2008; 51: 2163-2172.
12. Korfer R, El-Banayosy A, Arusoglu L, Minami K, Korner MM, Kizner L, et al. Single-center experience with the thoratec ventricular assist device. J Thorac Cardiovasc Surg 2000; 119: 596-600.
13. McBride LR, Naunheim KS, Fiore AC, Moroney DA, Swartz MT. Clinical experience with 111 Thoratec ventricular assist devices. Ann Thorac Surg 1999; 67: 1233-1238; discussion 1238-1239.
14. Frazier OH, Rose EA, Oz MC, Dembitsky W, McCarthy P, Radovancevic B, et al. Multicenter clinical evaluation of the Heart-mate vented electric left ventricular assist system in patients awaiting heart transplantation J Thorac Cardiovasc Surg 2001; 122: 1186-1195.
15. Nishinaka T, Schima H, Roethy W, Rajek A, Nojiri C, Wolner E, et al. The Duraheart VAD, a magnetically levitated centrifugal pump: The University of Vienna bridge-to-transplant experience. Circ J 2006; 70: 1421-1425.
16. Pagani FD, Miller LW, Russell SD, Aaronson KD, John R, Boyle AJ, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 2009; 54: 312-321.
17. Morshuis M, El-Banayosy A, Arusoglu L, Koerfer R, Hetzer R, Wieselthaler G, et al. European experience of duraheart magnetically levitated centrifugal left ventricular assist system. Eur J Cardiothorac Surg 2009; 35: 1020-1027; discussion 1027-1028.
18. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001; 345: 1435-1443.
19. Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-rematch era: Implications for patient selection Circulation 2007; 116: 497-505.
20. Saito S, Matsumiya G, Sakaguchi T, Miyagawa S, Yoshikawa Y, Yamauchi T, et al. Risk factor analysis of long-term support with left ventricular assist system. Circ J 2010; 74: 715-722.
21. Sasaoka T, Kato TS, Komamura K, Takahashi A, Nakajima I, Oda N, et al. Improved long-term performance of pulsatile extracorpo-real left ventricular assist device. J Cardiol 2010; 56: 220-228.
22. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction: Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1893-1900.
23. Lenzen MJ, Scholte op Reimer WJ, Boersma E, Vantrimpont PJ, Follath F, Swedberg K, et al. Differences between patients with a preserved and a depressed left ventricular function: A report from the Euroheart Failure Survey. Eur Heart J 2004; 25: 1214-1220.
24. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: A report from the Optimize-HF registry. J Am Coll Cardiol 2007; 50: 768-777.